Lilly to appeal FDA's approvable letter for Arxxant
Eli Lilly says it will appeal the FDA's decision to issue an "approvable letter" that requests an additional efficacy study for Arxxant, its new drug for moderate to severe nonproliferative diabetic retinopathy.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.